1. Home
  2. ANIX vs XGN Comparison

ANIX vs XGN Comparison

Compare ANIX & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Anixa Biosciences Inc.

ANIX

Anixa Biosciences Inc.

HOLD

Current Price

$3.52

Market Cap

108.5M

Sector

Health Care

ML Signal

HOLD

Logo Exagen Inc.

XGN

Exagen Inc.

HOLD

Current Price

$4.45

Market Cap

110.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANIX
XGN
Founded
1982
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.5M
110.7M
IPO Year
2013
2014

Fundamental Metrics

Financial Performance
Metric
ANIX
XGN
Price
$3.52
$4.45
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$8.67
$8.86
AVG Volume (30 Days)
300.9K
215.6K
Earning Date
05-27-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
12.82
N/A
EPS
N/A
N/A
Revenue
$210,000.00
N/A
Revenue This Year
N/A
$8.12
Revenue Next Year
N/A
$13.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.32
$2.59
52 Week High
$5.46
$12.23

Technical Indicators

Market Signals
Indicator
ANIX
XGN
Relative Strength Index (RSI) 58.95 48.27
Support Level $2.48 $4.08
Resistance Level $3.53 $4.93
Average True Range (ATR) 0.29 0.35
MACD 0.01 -0.01
Stochastic Oscillator 59.13 35.85

Price Performance

Historical Comparison
ANIX
XGN

About ANIX Anixa Biosciences Inc.

Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.

About XGN Exagen Inc.

Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.

Share on Social Networks: